# Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia

> **NCT00003991** · PHASE3 · COMPLETED · sponsor: **Maxim Pharmaceuticals** · enrollment: 360 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** aldesleukin
- **DRUG:** histamine dihydrochloride

## Key facts

- **NCT ID:** NCT00003991
- **Lead sponsor:** Maxim Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-07
- **Primary completion:** —
- **Final completion:** 2011-08
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2013-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003991, "Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00003991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*